as per annexure enclosed
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty 100 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals reported strong FY2026 results with consolidated revenue growing 15.8% to Rs 252,285 million and profit after tax surging 33% to Rs 20,027 million. Standalone revenue was Rs 93,262 million with PAT at Rs 14,926 million. The Board recommended a final dividend of Rs 10 per share (200%) bringing total dividend to Rs 20/share for FY26. Key strategic decisions include: merger of Apollo Hospitals North Limited (WOS) into the company; AHLL divesting stake in Apollo Specialty Hospitals and Apollo Fertility to Kids Clinic India (Cloudnine) for Rs 15,500 million enterprise value (cash + 9.9% equity); and continuation of the Composite Scheme for pharmacy distribution and digital health platform demerger into Apollo Healthtech Limited. Auditors issued unmodified opinion on both standalone and consolidated financial statements.
Strong financial performance with 33% PAT growth on consolidated basis signals operational strength. The multiple strategic transactions (merger, asset divestment, demerger scheme) indicate ongoing portfolio restructuring which could unlock value. No audit concerns with clean opinions supports financial credibility.